文献速递免疫规划慢病防控与筛查

巴西国家人乳头瘤病毒疫苗接种规划对20-24岁女性宫颈癌及宫颈上皮内瘤变3级发病率的影响:一项基于人群的研究

Effect of Brazil's national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20-24 years: a population-based study.
PubMed 文献 · Lancet Glob Health · 2025-01-01

该研究基于巴西诊断、治疗及住院数据库,分析2019至2023年20-24岁女性宫颈癌与宫颈上皮内瘤变3级(CIN3)发病率。比较2001-03出生队列与1994-98出生队列,宫颈癌发病率比为0.42(95%可信区间0.27-0.66),CIN3为0.33(0.20-0.53),并以乳腺癌为阴性对照结果接近无效。结论认为巴西HPV疫苗接种规划降低了该人群宫颈癌和CIN3发病率。

要点

  • 2001-03出生队列较1994-98队列宫颈癌发病率比为0.42(95%可信区间0.27-0.66)。
  • 同一比较中CIN3发病率比为0.33(95%可信区间0.20-0.53)。
  • 以乳腺癌为阴性对照结果接近无效,住院数据敏感性分析结果相似。

核心结论

  • 巴西HPV疫苗接种规划降低了20-24岁女性宫颈癌和CIN3发病率。
  • 作者认为这些发现强调疫苗在减少健康差异和助力中低收入人群消除宫颈癌方面的潜力。

研究设计与样本

  • 基于人群的研究,分析巴西诊断、治疗及住院数据库中2019至2023年20-24岁女性的宫颈癌和CIN3发病率。
  • 按出生年份划分出生队列,主要分析使用Painel Oncologia(诊断与治疗数据库)数据。
  • 采用贝叶斯负二项回归估计发病率比,调整日历年、年龄和诊断季度,并以乳腺癌作为阴性对照结果。

主要发现

  • 2001-03出生队列与1994-98出生队列比较,宫颈癌发病率比为0.42(95%可信区间0.27-0.66)。
  • 同一比较中CIN3发病率比为0.33(95%可信区间0.20-0.53)。
  • 阴性对照结果与暴露因素关联接近无效,可信区间较宽。
  • 使用住院数据的敏感性分析显示相似结果。

关键数值与推荐

  • 宫颈癌定义为ICD-10编码C53,CIN3定义为编码D06。
  • 主要结局为宫颈癌和CIN3的诊断。
  • 发病率比采用贝叶斯负二项回归估计,调整日历年、年龄和诊断季度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies from high-income countries have shown significant reductions in cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3) after implementing the human papillomavirus (HPV) vaccination. However, evidence from low-income and middle-income countries remains limited. Therefore, we aimed to evaluate the impact of the Brazilian HPV vaccination programme on the incidence of cervical cancer and CIN3. METHODS: In this population-based study, we analysed cervical cancer and CIN3 incidence among women aged 20-24 years between 2019 and 2023, using data from the diagnosis, treatment, and hospitalisations (ie, admittance to hospital) databases from Brazil. Birth cohorts were categorised according to the year of birth. The primary outcome was the diagnosis of cervical cancer (ICD-10 code C53) and CIN3 (code D06). Incidence rate ratios were estimated using Bayesian negative binomial regression, adjusting for calendar year, age, and trimester of diagnosis. We used breast cancer as a negative control outcome. The main analysis was conducted using the data from the Painel Oncologia (diagnosis and treatment database). FINDINGS: We analysed 60·6 million women-years of follow-up for women aged 20-24 years. 1318 cervical cancer and 2132 CIN3 cases were recorded. The incidence rate ratios comparing the 2001-03 birth cohort to the 1994-98 birth cohort were 0·42 (95% credible interval 0·27-0·66) for cervical cancer and 0·33 (0·20-0·53) for CIN3. The negative control outcome and exposure showed values close to the null with wider credible intervals. Sensitivity analyses using hospitalisation data showed similar results. INTERPRETATION: Brazil's HPV vaccination programme reduced cervical cancer and CIN3 incidence in women aged 20-24 years. These findings underscore the vaccine's potential to reduce health disparities and contribute to the elimination of cervical cancer in low-income and middle-income populations. FUNDING: Royal Society and Conselho Nacional de Desenvolvimento Científico e Tecnológico.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Cerqueira-Silva T, Barral-Netto M, Boaventura VS, et al. Effect of Brazil's national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20-24 years: a population-based study. Lancet Glob Health. 2025. PMID: 40975079. doi:10.1016/S2214-109X(25)00279-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。